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Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia 
chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability 
and low incidence of minor adverse events. Hemorrhage is thought to be a rare complica-
tion of IM. Recently, IM has been associated with reduced α2-plasmin inhibitor and plate-
let dysfunction. We report here the case of a 33-year-old female patient with CML who 
experienced subdural hematoma after an incremental increase in IM dosage due to a loss 
of complete molecular response. This case indicates that physicians should be alert to 
this atypical cause of headache in patients taking high-dose IM.
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INTRODUCTION
  Chronic myeloid leukemia (CML) is a myeloproliferative 
disease characterized by the presence of the Philadelphia 
chromosome, which results from the reciprocal chromosomal 
translocation t(9;22)(q34;q11) [1]. Imatinib mesylate (IM, 
Gleevec; Novartis, Switzerland) is a potent and selective ty-
rosine kinase inhibitor that acts on Bcr/Abl, the protein 
product of the Philadelphia chromosome. This drug has revo-
lutionized the treatment of CML and is now a standard 
initial treatment for CML [2]. In clinical trials using IM, 
common side effects of nausea, emesis, diarrhea, periorbital 
edema, fluid retention, and myelosuppression have been 
documented. Nevertheless, phase I and II studies have found 
IM to be well tolerated with most of the side effects being 
minor [3, 4].
  We report here an unusual case of subdural hematoma 
in a patient with CML treated with high-dose IM. To the 
best of our knowledge, this adverse event has not been pre-
viously reported in Korea.
CASE REPORT
  A 33-year-old woman was diagnosed in September 2004 
with chronic phase Philadelphia chromosome-positive CML, 
and IM was initiated at a dose of 400 mg daily. A complete 
cytogenetic response (CCyR) was achieved after 3 months 
of therapy. A complete molecular response (CMR) was ob-
tained after 12 months of therapy (in September 2005).
  In April 2009, a peripheral blood sample showed a positive 
result for BCR-ABL fusion transcript, as well as a loss of 
CMR. Cytogenetic examination of a bone marrow sample 
showed sustained CCyR. The treatment dosage was increased 
to 600 mg per day because of the loss of CMR and increased 
again to 800 mg per day 1 month later owing to the detection 
of an M351T IM-resistance mutation. In August 2009, fol-
low-up laboratory findings showed a slightly decreased quan-
tity of the BCR-ABL fusion transcript. However, the dose 
was reduced to 600 mg per day in September 2009 because 
the patient began to experience intolerable headaches. Four-
teen days after her last outpatient appointment, the patient 
complained of severe headache with nausea and vomiting. Korean J Hematol 2010;45:73-5.
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Fig. 1. Computed tomography and 
magnetic resonance imaging of the 
subdural hematoma. (A) Non-contrast
axial CT scan shows a crescent- 
shaped, chronic CSF-isodense left 
subdural hematoma (arrow). There 
is mild effacement of the left lateral 
ventricle. (B) Axial FLAIR MR shows
a chronic subdural hematoma with 
hyperintense signal (arrow).
She also developed a visual field defect, a black spot in her 
right eye and was accordingly referred to local ophthalmol-
ogy clinics. On ophthalmoscopic examination, optic disc 
swelling and hemorrhage were detected. She had no history 
of prior traumatic events or of anti-coagulation medication.
  She was subsequently transferred to our emergency center. 
On general examination, her blood pressure was found to 
be 150/90 mmHg and her heart rate was 80/min. Lung sounds 
were clear and heart sounds were normal. A neurologic 
examination was also normal. Laboratory data showed the 
following: hemoglobin, 11.4 g/dL; hematocrit, 33.6%; white 
blood cell count, 8.3×109/L (segmented neutrophils, 63.2%; 
lymphocytes, 25.2%; monocytes, 5.9%; eosinophils, 5.5%; 
basophils, 0.2%); platelets, 300×109/L; prothrombin time, 
11.1 sec (range, 9.8-13.5 sec); aPTT 26.3 sec (range, 21-32.4 
sec); fibrinogen, 258 (range, 200-400 mg/dL); FDP, 2 μg/ 
mL (range, ＜5  μg/mL); D-dimer, 0.2 μg/mL (range, ＜1 
μg/mL); serum sodium, 137 mEq/L; potassium, 3.7 mEq/L; 
chloride, 103 mEq/L; blood urea nitrogen, 8 mg/dL; serum 
creatinine, 0.9 mg/dL; total protein, 6.9 mg/dL; and albumin 
4.3, mg/dL. Urinalysis was normal. However, a subacute 
subdural hematoma was detected in the left frontotempor-
oparietal convexity on brain computed tomography and mag-
netic resonance images (Fig. 1). She was admitted to the 
department of neurosurgery. IM was discontinued for 2 days 
and then maintained at a dose of 400 mg daily, and the 
patient was managed conservatively for 1 week. As a con-
sequence of this treatment, her headache and visual symp-
toms were relieved. The IM dose was subsequently increased 
to 500 mg daily 1 month after the hemorrhagic event and 
increased again to 600 mg daily after a further month. In 
November 2009, she achieved CMR, as confirmed by RT- 
P C R .  S h e  i s  c u r r e n t l y  o n  a  m a i n t e n a n c e  d o s e  o f  I M  6 00  
mg daily and has experienced no significant adverse events.
DISCUSSION
  The incidence of subdural hematoma in the general pop-
ulation is estimated to be 1-15 cases per 100,000 patients 
[5]. The data indicate that for patients treated with IM, 
central nervous system hemorrhage occurs in 5% of those 
in blast crisis, 1% in the accelerated phase, and 0.6% in 
the chronic phase [6].
  Our patient developed subdural hematoma at an IM dose 
of 800 mg daily without thrombocytopenia or coagulation 
abnormalities. IM pharmacokinetic analysis in the IRIS study 
showed that hemorrhagic complications were not increased 
by higher IM trough levels at 400 mg daily during steady 
state [7]. That study showed that the frequency of grade 
3 or 4 hemorrhagic events was 0-1.1% during the first 3 
months and 1.1-2.2% during the 5-year treatment period 
according to trough level category. Song et al. [8] reported 
that 7 of 121 advanced CML patients treated with IM initially 
at 600 mg per day were diagnosed with non-traumatic sub-
dural hematomas. All patients had subdural hematomas that 
developed at a median of 10 weeks (1-48 weeks) after the 
start of therapy. In our patient, subdural hematoma devel-
oped at 20 weeks after increasing the IM dose to 800 mg 
daily. However, there is no definite evidence that a high 
IM trough level was associated with the development of 
major hemorrhagic events. 
  Interestingly, Radaelli et al. [9] reported that 10 (11%) 
of the 87 patients who had taken IM at a dose of 300-600 
mg daily for a minimum of 3 months developed unilateral 
or bilateral conjunctival hemorrhage. No other hemorrhagic 
events were observed during follow-up; the exception being 
conjunctival hemorrhage recurrence in 6 cases (7%). There-
fore, the authors decided not to stop using IM if only con-
junctival hemorrhage occurred in the absence of other major 
hemorrhagic events. Our patient discontinued the drug for 
2 days and was then put on a maintenance dose of 400 Korean J Hematol 2010;45:73-5.
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mg daily for 1 month. This was because the patient had 
previously experienced no adverse events at a dose of 400 
mg daily and had developed the subdural hematoma at a 
dose of 800 mg. We monitored the patient closely for addi-
tional hemorrhagic events and increased the dose of IM 
to 600 mg daily to prevent CML progression. Follow-up 
brain MRI showed complete resolution of the subdural hema-
toma after 1 month at a dose of 600 mg daily. 
  Matsue et al. [10] reported decreased levels of α2-plasmin 
inhibitor (α2-PI) in Philadelphia chromosome-positive 
lymphoblastic leukemia patients who had suffered hemor-
rhagic episodes while on an IM dose of 400 mg per day. 
The authors suggested that other predisposing factors might 
play a role in the development of clinical bleeding as abnor-
mal fibrinogenolysis is known to occur when plasma α2-PI 
levels fall below 60% of normal [11], and heterozygous pa-
tients with α2-PI deficiency exhibit hemorrhagic diathesis 
after events such as trauma, surgery, and dental extraction 
[12, 13]. In our patient, α2-PI was not checked at the time 
of the diagnosis of subdural hematoma. However, the α2-PI 
level was 108% (range, 80-120%) 2 months later when the 
patient was on an IM dose of 600 mg daily. 
  Recently, platelet aggregation dysfunction was reported 
in CML patients receiving dasatinib or IM [14]. Among the 
15 patients on IM (5 at 400 mg/day, 4 at 600 mg/day, and 
6 at 800 mg/day) not receiving aspirin, 10 had impaired 
arachidonic acid-induced platelet aggregation. Further inves-
tigations are needed in order to determine the mechanism 
of this platelet dysfunction. It leaves much to be desired 
that the platelet function tests were not performed at the 
time of the diagnosis of subdural hematoma in our case.
 This report describes the occurrence of a subdural hema-
toma in a CML patient treated with 800 mg IM daily with 
a background of normal coagulation and no history of recent 
trauma, thrombocytopenia, or anti-coagulation medication. 
This suggests that IM may cause subdural hematomas by 
an as yet unknown mechanism. It is interesting to note 
that IM produces hemostatic abnormalities independent of 
thrombocytopenia. Further investigations are needed to es-
tablish the mechanism of subdural hematoma causation, and 
also to examine the reduction in α2-PI levels and platelet 
aggregation dysfunction described above. This case indicates 
that physicians should be alert to this atypical cause of head-
ache in patients taking high-dose IM, including those who 
are in the advanced stage of CML.
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